SG11202109603SA - Pyrazine derivative and application thereof in inhibiting shp2 - Google Patents
Pyrazine derivative and application thereof in inhibiting shp2Info
- Publication number
- SG11202109603SA SG11202109603SA SG11202109603SA SG11202109603SA SG 11202109603S A SG11202109603S A SG 11202109603SA SG 11202109603S A SG11202109603S A SG 11202109603SA SG 11202109603S A SG11202109603S A SG 11202109603SA
- Authority
- SG
- Singapore
- Prior art keywords
- application
- pyrazine derivative
- inhibiting shp2
- shp2
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910160960.7A CN111647000B (zh) | 2019-03-04 | 2019-03-04 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| PCT/CN2020/077391 WO2020177653A1 (zh) | 2019-03-04 | 2020-03-02 | 吡嗪类衍生物及其在抑制shp2中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109603SA true SG11202109603SA (en) | 2021-10-28 |
Family
ID=72337672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109603S SG11202109603SA (en) | 2019-03-04 | 2020-03-02 | Pyrazine derivative and application thereof in inhibiting shp2 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220127276A1 (zh) |
| EP (1) | EP3936502A4 (zh) |
| JP (1) | JP2022523786A (zh) |
| KR (1) | KR20210135561A (zh) |
| CN (2) | CN111647000B (zh) |
| AU (1) | AU2020233038A1 (zh) |
| BR (1) | BR112021017495A2 (zh) |
| CA (1) | CA3132395A1 (zh) |
| CL (1) | CL2021002308A1 (zh) |
| CO (1) | CO2021013140A2 (zh) |
| IL (1) | IL286069A (zh) |
| MX (1) | MX2021010625A (zh) |
| SG (1) | SG11202109603SA (zh) |
| WO (1) | WO2020177653A1 (zh) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7386855B2 (ja) | 2018-09-29 | 2023-11-27 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物及び組成物の製造 |
| CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
| WO2022006780A1 (en) * | 2020-07-08 | 2022-01-13 | Novartis Ag | Manufacture of compounds and compositions for inhibiting activity of shp2 |
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| WO2022235817A1 (en) * | 2021-05-05 | 2022-11-10 | Huabio International, Llc | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors |
| JP2024516998A (ja) * | 2021-05-05 | 2024-04-18 | フヤバイオ インターナショナル，エルエルシー | Ｓｈｐ２阻害剤とｅｇｆｒチロシンキナーゼ阻害剤とを含む併用療法 |
| EP4333850A1 (en) * | 2021-05-05 | 2024-03-13 | Huyabio International, LLC | Shp2 inhibitor monotherapy and uses thereof |
| KR20240004960A (ko) | 2021-05-05 | 2024-01-11 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| CN115340559A (zh) * | 2021-05-12 | 2022-11-15 | 药雅科技(上海)有限公司 | Shp2磷酸酶杂环类抑制剂的制备及其应用 |
| CN115340561A (zh) * | 2021-05-14 | 2022-11-15 | 药雅科技(上海)有限公司 | Shp2磷酸酶稠环类抑制剂的制备及其应用 |
| CN114716448B (zh) * | 2021-05-13 | 2024-01-30 | 中国科学院上海药物研究所 | 抑制shp2活性的杂环化合物、其制备方法及用途 |
| TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023122938A1 (en) * | 2021-12-28 | 2023-07-06 | Js Innomed Holdings Ltd. | Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN115521305A (zh) * | 2022-09-20 | 2022-12-27 | 中国药科大学 | Shp2&nampt双靶向化合物及其药物组合物和用途 |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| CN115677661B (zh) * | 2022-10-27 | 2024-04-19 | 中国药科大学 | 杂环硫醚类化合物及其用途和药物组合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| JP6473457B2 (ja) * | 2014-01-17 | 2019-02-20 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物 |
| CN112625028A (zh) | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| EP4108659A1 (en) | 2016-06-07 | 2022-12-28 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| EA036446B1 (ru) * | 2016-06-14 | 2020-11-11 | Новартис Аг | Соединения и композиции для подавления активности shp2 |
| CN116478132A (zh) | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
| AU2018207464B2 (en) * | 2017-01-10 | 2020-05-14 | Novartis Ag | Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor |
| AU2018239542C1 (en) | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| EP3694848A1 (en) | 2017-10-12 | 2020-08-19 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| US11110171B2 (en) | 2017-12-21 | 2021-09-07 | New York University | PD-1 related cancer therapy |
| WO2019152454A1 (en) | 2018-01-30 | 2019-08-08 | Research Development Foundation | Shp2 inhibitors and methods of use thereof |
| US10561655B2 (en) | 2018-03-21 | 2020-02-18 | Synblia Therapeutics, Inc. | SHP2 inhibitors and uses thereof |
| AU2019251207A1 (en) | 2018-04-10 | 2020-11-19 | Revolution Medicines, Inc. | SHP2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with SHP2 mutations |
-
2019
- 2019-03-04 CN CN201910160960.7A patent/CN111647000B/zh active Active
-
2020
- 2020-03-02 CA CA3132395A patent/CA3132395A1/en active Pending
- 2020-03-02 BR BR112021017495A patent/BR112021017495A2/pt unknown
- 2020-03-02 MX MX2021010625A patent/MX2021010625A/es unknown
- 2020-03-02 WO PCT/CN2020/077391 patent/WO2020177653A1/zh unknown
- 2020-03-02 SG SG11202109603S patent/SG11202109603SA/en unknown
- 2020-03-02 KR KR1020217031808A patent/KR20210135561A/ko unknown
- 2020-03-02 JP JP2021551865A patent/JP2022523786A/ja active Pending
- 2020-03-02 US US17/436,223 patent/US20220127276A1/en active Pending
- 2020-03-02 CN CN202080014053.2A patent/CN113474338A/zh active Pending
- 2020-03-02 AU AU2020233038A patent/AU2020233038A1/en active Pending
- 2020-03-02 EP EP20766519.1A patent/EP3936502A4/en active Pending
-
2021
- 2021-09-02 IL IL286069A patent/IL286069A/en unknown
- 2021-09-03 CL CL2021002308A patent/CL2021002308A1/es unknown
- 2021-09-30 CO CONC2021/0013140A patent/CO2021013140A2/es unknown
-
2023
- 2023-01-25 US US18/101,511 patent/US11827644B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111647000B (zh) | 2021-10-12 |
| CN111647000A (zh) | 2020-09-11 |
| KR20210135561A (ko) | 2021-11-15 |
| US11827644B2 (en) | 2023-11-28 |
| AU2020233038A1 (en) | 2021-10-21 |
| MX2021010625A (es) | 2021-10-26 |
| CO2021013140A2 (es) | 2021-11-30 |
| US20220127276A1 (en) | 2022-04-28 |
| CN113474338A (zh) | 2021-10-01 |
| EP3936502A1 (en) | 2022-01-12 |
| BR112021017495A2 (pt) | 2021-12-14 |
| EP3936502A4 (en) | 2023-02-15 |
| JP2022523786A (ja) | 2022-04-26 |
| CA3132395A1 (en) | 2020-09-10 |
| WO2020177653A1 (zh) | 2020-09-10 |
| US20230227464A1 (en) | 2023-07-20 |
| CL2021002308A1 (es) | 2022-05-20 |
| IL286069A (en) | 2021-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286069A (en) | Consequence of pyrazine and its application in shp2 inhibition | |
| EP3768664A4 (en) | SHP2 INHIBITORS AND THEIR USES | |
| IL277551A (en) | Tri-specific binding molecules against cancer and their uses | |
| IL273664A (en) | Fill-finish assemblies and related methods | |
| SG11202001282UA (en) | Shp2 inhibitor compositions and methods for treating cancer | |
| EP3474900A4 (en) | DEGRADATION OF PROTEIN 9 (BRD9) CONTAINING BROMANOMAIN BY CONJUGATING BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHOD FOR USE THEREOF | |
| IL286077A (en) | Carboxamide-pyrimidine history and their use as shp2 antagonists | |
| EP4056563A4 (en) | COMPOUND USED AS SHP2 INHIBITOR AND ITS USE | |
| IL277493B (en) | Pyridine carbonyl history and their medicinal uses as trpc6 inhibitors | |
| EP3250609A4 (en) | Il13ra alpha 2 binding agents and use thereof in cancer treatment | |
| HK1257176A1 (zh) | 貽貝粘蛋白產品及其抑制粘膜炎症的應用 | |
| EP3552626A4 (en) | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR | |
| IL283533A (en) | Pentatein derivatives and their uses | |
| IL287543A (en) | Preparations and methods for reducing biological load in chromatography | |
| IL284994A (en) | Pyrrolopyrimidine derivative and its use | |
| PL3400835T3 (pl) | Okucie obrotowe i mebel | |
| EP3897670A4 (en) | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS | |
| IL285595A (en) | Spt5 inhibitors and uses thereof | |
| IL292198A (en) | Tim-3 inhibitors and their uses | |
| GB201820659D0 (en) | Novel compostions and their use in therapy | |
| EP3645120A4 (en) | NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION | |
| SG11202002422WA (en) | Novel phenylpyridine derivative and pharmaceutical composition comprising the same | |
| EP3536329A4 (en) | ANTI-DRUG AGENT WITH HVJ-E AND IMMUNCHECKPOINT PROTEIN INHIBITOR | |
| EP3829397A4 (en) | IMPROVED FURNITURE COMPONENTS AND ARRANGEMENTS | |
| EP3692142A4 (en) | MODIFIED POLYPEPTIDES OF DECARBOXYLASE AND THEIR APPLICATION IN THE PREPARATION OF BETA-ALANINE |